One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients

In this randomized, double-blind, multicenter study, H. pylori-positive patients with an active duodenal ulcer (DU) received esomeprazole, 20 mg twice daily (bid), or omeprazole, 20 mg bid, with amoxicillin, 1000 mg bid, and clarithromycin, 500 mg bid, for 1 week (EAC and OAC, respectively). Patient...

Full description

Saved in:
Bibliographic Details
Published in:Digestive diseases and sciences 2007-06, Vol.52 (6), p.1505-1512
Main Authors: Subei, Iyad M, Cardona, Hector José, Bachelet, Ernesto, Useche, Emerson, Arigbabu, Anthony, Hammour, Adnan Abu, Miller, Tom
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Ulcer Agents - administration & dosage
Anti-Ulcer Agents - adverse effects
Double-Blind Method
Duodenal Ulcer - drug therapy
Duodenal Ulcer - microbiology
Esomeprazole
Female
Helicobacter
Helicobacter Infections - drug therapy
Helicobacter Infections - ethnology
Helicobacter Infections - microbiology
Helicobacter pylori
Helicobacter pylori - drug effects
Humans
Male
Middle Aged
Omeprazole - administration & dosage
Omeprazole - adverse effects
Ulcers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this randomized, double-blind, multicenter study, H. pylori-positive patients with an active duodenal ulcer (DU) received esomeprazole, 20 mg twice daily (bid), or omeprazole, 20 mg bid, with amoxicillin, 1000 mg bid, and clarithromycin, 500 mg bid, for 1 week (EAC and OAC, respectively). Patients received an additional 3 weeks of either placebo or omeprazole, 20 mg once daily (od), in the EAC and OAC groups, respectively. The intent-to-treat population included 374 patients (EAC, 186; OAC, 188). Four-week DU healing rates were similar in the EAC+placebo and OAC+omeprazole groups: 74% and 76%, respectively. DU healing rates at 8 weeks were 87% for EAC+placebo and 88% for OAC+omeprazole. H. pylori eradication rates were 75% and 79% for EAC and OAC, respectively. Both regimens were well tolerated. A 1-week regimen of esomeprazole-based H. pylori eradication triple therapy was as effective for DU healing and eradication of H. pylori as omeprazole-based triple therapy followed by an additional 3 weeks of monotherapy.
ISSN:0163-2116
1573-2568
DOI:10.1007/s10620-006-9522-5